879892-86-1

Basic information

• Product Name: Phenol, 3-[1-(4-methoxyphenyl)-2-phenyl-1-butenyl]-
• CAS NO: 879892-86-1
• Molecular Formula: C23H22O2
• Molecular Weight: 330.426
• Mol File: 879892-86-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Phenol, 3-[1-(4-methoxyphenyl)-2-phenyl-1-butenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Phenol, 3-[1-(4-methoxyphenyl)-2-phenyl-1-butenyl]-(879892-86-1)
• EPA Substance Registry System: Phenol, 3-[1-(4-methoxyphenyl)-2-phenyl-1-butenyl]-(879892-86-1)

Safety Data

• Hazardous Substances Data: 879892-86-1(Hazardous Substances Data)

Upstream product

• 103-82-2 phenylacetic acid 
• 134518-89-1 3-pivaloyloxybenzaldehyde 
• 100-66-3 methoxybenzene 
• 693818-54-1 4-(4-methoxyphenyl)-3-phenyl-4-(3-pivaloyloxyphenyl)but-1-ene 
• 40595-34-4 (E)-trimethyl(3-phenylallyl)silane 

Downstream Products

• 82413-20-5 Droloxifene 
• 879892-92-9 3,5-dinitro-benzoic acid 3-{1-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2-phenyl-but-1-enyl}-phenyl ester 
• 879892-90-7 3,5-Dinitro-benzoic acid 3-[(E)-1-(4-hydroxy-phenyl)-2-phenyl-but-1-enyl]-phenyl ester 
• 879892-96-3 2,2-dimethyl-propionic acid 3-{1-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2-phenyl-but-1-enyl}-phenyl ester 
• 879893-00-2 2,2-Dimethyl-propionic acid 3-{(E)-1-[4-(2-dimethylamino-ethoxy)-phenyl]-2-phenyl-but-1-enyl}-phenyl ester 
• 879892-94-1 3-{1-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2-phenyl-but-1-enyl}-phenol 
• 879892-98-5 2,2-Dimethyl-propionic acid 3-[(E)-1-(4-hydroxy-phenyl)-2-phenyl-but-1-enyl]-phenyl ester 
• 879892-88-3 3,5-Dinitro-benzoic acid 3-[(E)-1-(4-methoxy-phenyl)-2-phenyl-but-1-enyl]-phenyl ester 

Relevant articles and documents

Searching for an ideal SERM: Mining tamoxifen structure–activity relationships

The repurposing of old drugs for new treatments has recently garnered increased attention in the face of new diseases and declining productivity of the pharmaceutial industry. This report draws attention to potential opportunities hiding in plain sight within the SAR of off-patent drugs. Herein we explore the untapped potential of Selective Estrogen Receptor Modulators (SERMs). SERMs are a class of molecules that have been highly influential in the treatment of estrogen receptor-positive breast cancers. However, the most commonly prescribed SERM, tamoxifen, has been found to increase the risk of endometrial cancer. Another SERM, raloxifene, does not increase incidence of endometrial cancer, but has been abandoned as a breast cancer treatment. We report the design, synthesis, and evaluation of an unexplored tamoxifen substitution pattern which mimics the geometry of raloxifene to confer its favorable pharmacodynamics. This substitution pattern was found to maintain excellent binding affinity to estrogen receptor-α.

Short-step synthesis of droloxifene via the three-component coupling reaction among aromatic aldehyde, cinnamyltrimethylsilane, and β-chlorophenetole

A short-step route for the preparation of droloxifene has been established via the novel three-component coupling reaction among 3-pivaloyloxybenzaldehyde, cinnamyltrimethylsilane, and β-chlorophenetole, the successive installation of the side-chain part, and the base-induced migration of the double bond. The present synthesis of tetra-substituted ethylene moieties is a widely applicable strategy for producing a variety of SERMs (selective estrogen receptor modulators) and SARMs (selective androgen receptor modulators), such as tamoxifen, raloxifene, and other compounds that can lead to new drugs.